India approves world's first synthetic CBD oral solution for anxiety
India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved a synthetic cannabidiol (CBD) oral solution developed by Hyderabad-based Leiutis Pharmaceuticals (with Zenara Pharma) for the management of mild-to-moderate anxiety disorders — the world's first regulatory approval of a fully synthetic CBD therapy. Announced around 15 July 2026, the drug uses a fully synthetic CBD (no cannabis plant material), was researched, developed, patented and clinically validated in India (Phase III done, Phase IV to follow), and its prescription is restricted to psychiatrists.
Key Facts & Details
7 points- 1CDSCO approved a synthetic CBD oral solution for mild-to-moderate anxiety disorders.
- 2It is the world's first approval of a fully synthetic cannabidiol therapy.
- 3It was developed by Hyderabad-based Leiutis Pharmaceuticals (with Zenara Pharma).
- 4The drug uses fully synthetic CBD (no cannabis plant material) and is non-psychoactive.
- 5It was developed and clinically validated in India; prescription limited to psychiatrists.
Deep Dive
- +The approval is based on a Phase III trial in India, with a Phase IV study to follow.
- +A synthetic API avoids reliance on cannabis cultivation.
Exam Focus
India approved the world's first synthetic version of which compound as an oral solution for anxiety in July 2026?
Related Topics
Exam Relevance & Angle
A world-first drug approval with an India-development angle is a high-value S&T/health GA item.
Target Exams
Background & Context
Cannabidiol (CBD) is a non-psychoactive cannabis compound; a fully synthetic CBD avoids plant-derived material.
Test Yourself
1 / 1In July 2026, India's CDSCO approved the world's first synthetic oral solution of which compound for anxiety?
Source
This topic is important for:
